Voyager Therapeutics’ (VYGR) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research note released on Tuesday,Benzinga reports. The firm currently has a $25.00 price objective on the stock.

Separately, Wall Street Zen raised Voyager Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Voyager Therapeutics has an average rating of “Hold” and an average price target of $16.50.

Voyager Therapeutics Stock Performance

Shares of NASDAQ VYGR opened at $3.92 on Tuesday. The company has a market cap of $233.63 million, a P/E ratio of -1.93 and a beta of 1.32. Voyager Therapeutics has a 52-week low of $2.64 and a 52-week high of $5.55. The firm’s fifty day moving average is $3.92 and its two-hundred day moving average is $4.19.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Monday, March 9th. The company reported ($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.08. The firm had revenue of $13.46 million during the quarter, compared to analyst estimates of $10.49 million. Voyager Therapeutics had a negative return on equity of 51.35% and a negative net margin of 296.53%. As a group, analysts forecast that Voyager Therapeutics will post -0.91 EPS for the current fiscal year.

Insider Activity at Voyager Therapeutics

In other news, CEO Alfred Sandrock sold 14,197 shares of the firm’s stock in a transaction on Tuesday, February 24th. The stock was sold at an average price of $3.79, for a total transaction of $53,806.63. Following the completion of the transaction, the chief executive officer directly owned 484,060 shares in the company, valued at $1,834,587.40. This trade represents a 2.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Over the last quarter, insiders sold 49,783 shares of company stock valued at $188,694. Corporate insiders own 4.53% of the company’s stock.

Hedge Funds Weigh In On Voyager Therapeutics

Several large investors have recently bought and sold shares of VYGR. Los Angeles Capital Management LLC acquired a new stake in Voyager Therapeutics during the 2nd quarter worth $50,000. Coldstream Capital Management Inc. acquired a new position in shares of Voyager Therapeutics during the third quarter worth about $55,000. CIBC Asset Management Inc purchased a new stake in shares of Voyager Therapeutics in the fourth quarter valued at approximately $45,000. Wexford Capital LP purchased a new stake in shares of Voyager Therapeutics in the third quarter valued at approximately $42,000. Finally, Caitong International Asset Management Co. Ltd lifted its holdings in Voyager Therapeutics by 42,410.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 15,729 shares of the company’s stock valued at $62,000 after acquiring an additional 15,692 shares during the period. Hedge funds and other institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.